mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for MAPK9
Gene summary
Basic gene Info.Gene symbolMAPK9
Gene namemitogen-activated protein kinase 9
SynonymsJNK-55|JNK2|JNK2A|JNK2ALPHA|JNK2B|JNK2BETA|PRKM9|SAPK|SAPK1a|p54a|p54aSAPK
CytomapUCSC genome browser: 5q35
Type of geneprotein-coding
RefGenesNM_001135044.1,
NM_002752.4,NM_139068.2,NM_139069.2,NM_139070.2,
DescriptionJun kinaseMAP kinase 9MAPK 9c-Jun N-terminal kinase 2c-Jun kinase 2stress-activated protein kinase 1astress-activated protein kinase JNK2
Modification date20141207
dbXrefs MIM : 602896
HGNC : HGNC
Ensembl : ENSG00000050748
HPRD : 04206
Vega : OTTHUMG00000130934
ProteinUniProt: P45984
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_MAPK9
BioGPS: 5601
PathwayNCI Pathway Interaction Database: MAPK9
KEGG: MAPK9
REACTOME: MAPK9
Pathway Commons: MAPK9
ContextiHOP: MAPK9
ligand binding site mutation search in PubMed: MAPK9
UCL Cancer Institute: MAPK9
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID
GO:0007254JNK cascade8654373


Top
Ligand binding site mutations for MAPK9

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
K55K56ECOAD2
K55K56RCOAD2
L142H143LHNSC1
L77C79FLUAD1
E73R72CSKCM1
N114C116YSTAD1
K55,A53V54DSTAD1
R69A67TUCEC1
E109E109KUCEC1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for MAPK9
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
E73R72C0.14617348
K55V54D-1.6087828
A53V54D-1.6087828
E109E109K-1.2344024
L77C79F-0.94448751
N114C116Y-0.9233146
R69A67T-0.63213118
K55K56E-0.25808379
K55K56R-0.17107702
L142H143L-0.16623519
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for MAPK9 from PDB
PDB IDPDB titlePDB structure
3E7OCrystal Structure of JNK2

Top
Differential gene expression and gene-gene network for MAPK9
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of MAPK9 and the right PPI network was created from samples without mutations in the LBS of MAPK9. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for MAPK9
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0032927Precancerous Conditions2Biomarker
umls:C0035126Reperfusion Injury2Biomarker
umls:C0022116Ischemia1Biomarker
umls:C0027055Myocardial Reperfusion Injury1Biomarker
umls:C0027627Neoplasm Metastasis1Therapeutic

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for MAPK9
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ExperimentalDB07020N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamideSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of MAPK9 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
35FN-{3-[5-(1H-1,2,4-TRIAZOL-3-YL)-1H-INDAZOL-3-YL]PHENYL}FURAN-2-CARBOXAMIDE3e7oBA53 E109
35FN-{3-[5-(1H-1,2,4-TRIAZOL-3-YL)-1H-INDAZOL-3-YL]PHENYL}FURAN-2-CARBOXAMIDE3e7oAA53 E109 N114
B961-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA3npcBA53 K55 R69 E73 L77
B961-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA3npcAA53 K55 R69 E73 L77 L142


Top
Conservation information for LBS of MAPK9
Multiple alignments for P45984 in multiple species
LBSAA sequence# speciesSpecies
A113MELMDANLCQV4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
A53LGINVAVKKLS4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
D112VMELMDANLCQ4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
D169TLKILDFGLAR4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
E109VYLVMELMDAN4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
E73KRAYRELVLLK4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
F170LKILDFGLART4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
I32QQLKPIGSGAQ4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
I86NHKNIISLLNV4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
K55INVAVKKLSRP4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
L106FQDVYLVMELM4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
L110YLVMELMDANL4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
L142CGIKHLHSAGI4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
L168CTLKILDFGLA4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
L76YRELVLLKCVN4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
L77RELVLLKCVNH4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
M108DVYLVMELMDA4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
M111LVMELMDANLC4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
N114ELMDANLCQVI4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
R69QTHAKRAYREL4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
V158KPSNIVVKSDC4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
V40GAQGIVCAAFD4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas